


<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) or 1.97(c))				Docket No. 21349/17	
In Re Application Of: Jean-Louis Escary					
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/534,098	May 6, 2005	N/A	21710	N/A	N/A
Title: <b>METHOD FOR PROVIDING NATURAL THERAPEUTIC AGENTS WITH HIGH TEMPERATURE INDEX</b>					
<div style="text-align: center;"> <p>Address to:</p> <p><b>Commissioner for Patents</b>            P.O. Box 1450            Alexandria, VA 22313-1450</p> </div> <div style="text-align: center; margin-top: 10px;"> <p><b>37 CFR 1.97(b)</b></p> <p>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> </div> <div style="text-align: center; margin-top: 20px;"> <p><b>37 CFR 1.97(c)</b></p> <p>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <div style="margin-left: 40px;"> <p><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p style="text-align: center; margin: 10px 0;"><b>OR</b></p> <p><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p> </div> </div>					

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
21349/17

In Re Application of: Jean-Louis Escary



Application No. 10/534,098	Filing Date May 6, 2005	Examiner N/A	Customer No. 21710	Group Art Unit N/A	Confirmation No. N/A
-------------------------------	----------------------------	-----------------	-----------------------	-----------------------	-------------------------

Title: **METHOD FOR PROVIDING NATURAL THERAPEUTIC AGENTS WITH HIGH TEMPERATURE INDEX**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached. 50-0369
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. \_\_\_\_\_ as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature of Person Mailing Correspondence

Seema M. Shah

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

\_\_\_\_\_  
Signature

Dated: 7-28-2005

John C. Serio, Reg. No. 39,023  
Attorney for Applicant(s)  
Brown Rudnick Berlack Israels LLP  
One Financial Center, Box IP  
Boston, MA 02111  
Tel: 617-856-8238  
Fax: 617-856-8201  
Email: jserio@brownrudnick.com

CC:

**FORM PTO-1449**  
**INFORMATION DISCLOSURE STATEMENT**

ATTY DOCKET NO.

21349/17

SERIAL NO.

10/534,098

APPLICANT(S): Jean-Louis Escary

FILING DATE:

May 6, 2005

ART UNIT:

## UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL	DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N
	WO 02/086156	2002/10/31	PCT	C12Q	1/68	Y
	WO 02/079249	2002/10/10	PCT	C07K	14/56	Y

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

	Ortaldo J R et al.: "Effects of Several Species of Human Leukocyte Interferon on Cytotoxic Activity of Natural Killer Cells and Monocytes" International Journal of Cancer, vol. 31, no. 3, 1983, pages 285-290
	Pestka S: "The Human Interferons—From Protein Purification and Sequence to Cloning and Expression in Bacteria; Before, Between, and Beyond." Archives of Biochemistry and Biophysics. vol. 221, no. 1, 15 February 1983, pages 1-37.
	Sperber S J et al.: "Anti-HIV-1 Activity of Recombinant and Hybrid Species of Interferon-Alpha" Journal of Interferon Research, vol. 12, 1992, pages 363-368
	Evinger M et al.: "Antiproliferative and Antiviral Activities of Human Leukocyte Interferons" Archives of Biochemistry and Biophysics, vol. 210, no. 1, 1981, pages 319-329,

Examiner:

Date: